Agilent Technologies, Inc. $A Shares Sold by Kestra Advisory Services LLC

Key Points

• Kestra Advisory Services LLC has reduced its stake in Agilent Technologies by 26.9%, now holding 12,721 shares worth approximately $1.49 million.
• Several hedge funds increased their holdings in Agilent during Q1, with Candriam S.C.A. leading with a 134.3% increase, owning 520,956 shares valued at around $60.94 million.
• Analysts have mixed views on Agilent, with price target revisions, including UBS lowering it from $150.00 to $130.00 while TD Cowen increased theirs to $150.00, giving it a "buy" rating.

Kestra Advisory Services LLC reduced its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 26.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,721 shares of the medical research company's stock after selling 4,691 shares during the period. Kestra Advisory Services LLC's holdings in Agilent Technologies were worth $1,488,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Valeo Financial Advisors LLC lifted its position in shares of Agilent Technologies by 3.0% in the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company's stock worth $403,000 after purchasing an additional 102 shares in the last quarter. Cary Street Partners Financial LLC lifted its holdings in shares of Agilent Technologies by 2.9% in the first quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company's stock worth $431,000 after acquiring an additional 103 shares during the last quarter. Western Pacific Wealth Management LP raised its holdings in Agilent Technologies by 15.2% in the 1st quarter. Western Pacific Wealth Management LP now owns 873 shares of the medical research company's stock valued at $102,000 after buying an additional 115 shares during the last quarter. Bartlett & CO. Wealth Management LLC grew its position in shares of Agilent Technologies by 5.1% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company's stock worth $281,000 after buying an additional 116 shares during the period. Finally, Brighton Jones LLC grew its position in shares of Agilent Technologies by 2.6% during the 1st quarter. Brighton Jones LLC now owns 4,784 shares of the medical research company's stock worth $560,000 after buying an additional 121 shares during the period. Institutional investors and hedge funds own 87.41% of the company's stock.

Agilent Technologies Trading Up 1.9%

Agilent Technologies stock traded up $2.32 during mid-day trading on Thursday, hitting $127.54. The company's stock had a trading volume of 1,205,078 shares, compared to its average volume of 1,953,163. The company has a 50 day moving average of $118.85 and a 200-day moving average of $116.42. The stock has a market cap of $36.23 billion, a PE ratio of 29.96, a P/E/G ratio of 3.91 and a beta of 1.24. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.60 and a current ratio of 2.25. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. During the same period in the prior year, the business posted $1.32 EPS. The firm's quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.26% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Evercore ISI dropped their price objective on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research note on Thursday, August 28th. Robert W. Baird upped their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Wells Fargo & Company increased their price target on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. TD Cowen increased their price objective on Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Finally, Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $139.25.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.